# A Phase 2 Study of HX301 in Patients with High-grade Giloma

> **NCT06703255** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hangzhou Hanx Biopharmaceuticals, Ltd.** · enrollment: 72 (estimated)

## Conditions studied

- Glioma

## Interventions

- **DRUG:** HX301+/Temozolomide

## Key facts

- **NCT ID:** NCT06703255
- **Lead sponsor:** Hangzhou Hanx Biopharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-08
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06703255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06703255, "A Phase 2 Study of HX301 in Patients with High-grade Giloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06703255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*